Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance

Molecular Therapy

Volumn 17, Issue 1, 2009, Pages 131-143

  Cornils, Kerstin ^a,b   Lange, Claudia ^b   Schambach, Axel ^c   Brugman, Martijn H ^c   Nowak, Regine ^a   Lioznov, Michael ^b   Baum, Christopher ^c,d   Fehse, Boris ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CLONAL VARIATION; CONTROLLED STUDY; DNA INTEGRATION; FEMALE; GENE EXPRESSION REGULATION; GENE INSERTION; GENE LOCUS; GENETIC MARKER; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMOGENESIS; LONG TERMINAL REPEAT; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED C57BL; MUTAGENESIS, INSERTIONAL; POLYMERASE CHAIN REACTION; RETROVIRIDAE; TRANSCRIPTION, GENETIC;

MURINAE;

EID: 58149236900     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.238     Document Type: Article

References (50)

1. Dick, JE, Magli, MC, Huszar, D, Phillips, RA and Bernstein, A (1985). Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 42: 71-79.
2. Lemischka, IR, Raulet, DH and Mulligan, RC (1986). Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 45: 917-927.
3. Tey, SK and Brenner, MK (2007). The continuing contribution of gene marking to cell and gene therapy. Mol Ther 15: 666-676.
4. Hacein-Bey-Abina, S, Le Deist, F, Carlier, F, Bouneaud, C, Hue, C, De Villartay, JP et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
5. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning (2002). Science 296: 2410-2413.
6. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
7. Li, Z, Düllmann, J, Schiedlmeier, B, Schmidt, M, von Kalle, C, Meyer, J et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
8. Kustikova, O, Fehse, B, Modlich, U, Yang, M, Düllmann, J, Kamino, K et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174.
9. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
10. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
11. Newrzela, S, Cornils, K, Li, Z, Baum, C, Brugman, MH, Hartmann, M et al. (2008). Resistance of mature T cells to oncogene transformation. Blood 112: 2278-2286.
12. Baum, C, Düllmann, J, Li, Z, Fehse, B, Meyer, J, Williams, DA et al. (2003). Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101: 2099-2114.
13. Baum, C, Kustikova, O, Modlich, U, Li, Z and Fehse, B (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17: 253-263.
14. Baum, C, von Kalle, C, Staal, FJ, Li, Z, Fehse, B, Schmidt, M et al. (2004). Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 9: 5-13.
15. Deichmann, A, Hacein-Bey-Abina, S, Schmidt, M, Garrigue, A, Brugman, MH, Hu, J et al. (2007). Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117: 2225-2232.
16. Aiuti, A, Cassani, B, Andolfi, G, Mirolo, M, Biasco, L, Recchia, A et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117: 2233-2240.
17. Schwarzwaelder, K, Howe, SJ, Schmidt, M, Brugman, MH, Deichmann, A, Glimm, H et al. (2007). Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117: 2241-2249.
18. Nienhuis, AW, Dunbar, CE and Sorrentino, BP (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13: 1031-1049.
19. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knöss, S, Schambach, A et al. (2006). Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2453.
20. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16: 718-725.
21. Modlich, U, Schambach, A, Brugman, MH, Wicke, DC, Knoess, S, Li, Z et al. (2008). Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 8: 1519-1528.
22. Li, Z, Fehse, B, Schiedlmeier, B, Düllmann, J, Frank, O, Zander, AR et al. (2002). Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cell. Leukemia 16: 1655-1663.
23. Schambach, A, Mueller, D, Galla, M, Verstegen, MM, Wagemaker, G, Loew, R et al. (2006). Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 13: 1524-1533.
24. Schambach, A, Wodrich, H, Hildinger, M, Bohne, J, Kräusslich, HG and Baum, C (2000). Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2: 435-445.
25. Kustikova, O, Geiger, H, Li, Z, Brugman, MH, Chambers, SM, Shaw, CA et al. (2007). Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood 109: 1897-1907.
26. Kustikova, OS, Baum, C and Fehse, B (2008). Retroviral integration site analysis in hematopoietic stem cells. Methods Mol Biol 430: 255-267.
27. Purton, LE and Scadden, DT (2007). Limiting factors in murine hematopoietic stem cell assays. Cell Stem Cell 1: 263-270.
28. McKenzie, JL, Gan, OI, Doedens, M, Wang, JC and Dick, JE (2006). Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol 7: 1225-1233.
29. Akagi, K, Suzuki, T, Stephens, RM, Jenkins, NA and Copeland, NG (2004). RTCGD: Retroviral tagged cancer gene database. Nucleic Acids Res 32: D523-D527.
30. Hammond, SM, Crable, SC and Anderson, KP (2005). Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia. Leuk Res 29: 89-97.
31. Cattoglio, C, Facchini, G, Sartori, D, Antonelli, A, Miccio, A, Cassani, B et al. (2007). Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110: 1770-1778.
32. Mitchell, RS, Beitzel, BF, Schroder, AR, Shinn, P, Chen, H, Berry, CC et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2: E234.
33. Chambers, SM, Boles, NC, Lin, KY, Tierney, MP, Bowman, TV, Bradfute, SB et al. (2007). Hematopoietic fingerprints: An expression database of stem cells and their progeny. Cell Stem Cell 1: 578-591.
34. Fraser, C, Szilvassy, S, Eaves, C and Humphries, R (1992). Proliferation of totipotent hematopoietic stem cells in vitro with retention of long-term competitive in vivo reconstituting ability. Proc Natl Acad Sci USA 89: 1968-1972.
35. Goebel, WS, Yoder, MC, Pech, NK and Dinauer, MC (2002). Donor chimerism and stem cell function in a murine congenic transplantation model after low-dose radiation conditioning: Effects of a retroviral-mediated gene transfer protocol and implications for gene therapy. Exp Hematol 30: 1324-1332.
36. Gaspar, HB, Bjorkegren, E, Parsley, K, Gilmour, KC, King, D, Sinclair, J et al. (2006). Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 14: 505-513.
37. Seggewiss, R, Pittaluga, S, Adler, RL, Guenaga, FJ, Ferguson, C, Pilz, IH et al. (2006). Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 107: 3865-3867.
38. van der Putten, H, Quint, W, van Raaij, J, Maandag, ER, Verma, IM and Berns, A (1981). M-MuLV-induced leukemogenesis: Integration and structure of recombinant proviruses in tumors. Cell 24: 729-739.
39. Kohn, DB, Sadelain, M, Dunbar, C, Bodine, D, Kiem, HP, Candotti, F et al. (2003). American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 8: 180-187.
40. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2008). The genotoxic potential of integrative vectors is strongly modulated by vector design and the profile of integration site selection. Mol Ther 16 (suppl. 1): S362.
41. Hargrove, PW, Kepes, S, Hanawa, H, Obenauer, JC, Pei, D, Cheng, C et al. (2008). Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 16: 525-533.
42. Mooslehner, K, Karls, U and Harbers, K (1990). Retroviral integration sites in transgenic Mov mice frequently map in the vicinity of transcribed DNA regions. J Virol 64: 3056-3058.
43. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
44. Berry, C, Hannenhalli, S, Leipzig, J and Bushman, FD (2006). Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol 2: E157.
45. Recchia, A, Cittaro, D, Cattoglio, C, Felice, B, Miccio, A, Ferrari, G et al. (2008). Integration of retroviral vectors into the human genome is biased by specific subsets of transcription factor binding sites. Mol Ther 16 (suppl. 1): S360.
46. Wang, GP, Garrigue, A, Ciuffi, A, Ronen, K, Leipzig, J, Berry, C et al. (2008). DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res 36: e49.
47. Beyer, W, Westphal, M, Ostertag, W and von Laer, D (2002). Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: Generation, concentration, and broad host range. J Virol 76: 1488-1495.
48. Li, Z, Schwieger, M, Lange, C, Kraunus, J, Sun, H, van den Akker, E et al. (2003). Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol 31: 1206-1214.
49. Pfaffl, MW (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: E45.
50. R Development Core Team (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, .